Сormorant Asset Management, an investment manager, led a $62m Series B funding round in Immuneering, a firm that is creating better medicines through insights from bioinformatics. The round had participation from Surveyor Capital, Rock Springs, funds and accounts managed by BlackRock, Perceptive Advisors and LYFE Capital. Existing investors and senior management also participated in the financing. “Our Disease Cancelling Technology platform has provided insights into therapies that can offer differentiated efficacy and safety with drugs targeting cancers driven by alterations that activate the RAS/MAPK pathway. We are pleased to have such strong support from both our current and new investors as we begin our next phase of growth and advance our leading program targeting MEK into the clinic," Ben Zeskind, Immuneering Co-founder and CEO.